Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms (PhiNESS)

University Hospital of Bordeaux

Status: Completed

Conditions: Polycythemia Vera; Essential Thrombocythemia

Treatments: Biological: RNA sample of total leukocytes before start of treatment

Study type: Observational

Funder types: Other

Identifiers

NCT02823184

CHUBX 2014/27

Details and patient eligibility

About

The aim of this study is to evaluate the endoplasmic reticulum stress markers as predictive for response to hydroxyurea in polycythemia vera (PV) and essential thrombocythemia (ET).

Full description

The recent discovery of calreticulin mutations in myeloproliferative neoplasms point to the unexpected role of the endoplasmic reticulum biology in the pathophysiology in these diseases. Otherwise, the association of endoplasmic reticulum stress with solid cancers, in particular in resistance to chemotherapy, is well documented, contrary to hematological malignancies. The study aims to evaluate endoplasmic reticulum stress markers as predictors for the response to hydroxyurea in polycythemia vera and essential thrombocythemia patients. The main objective is to correlate endoplasmic reticulum stress (defined as splicing of XBP1 above 30%) to the rate of complete response after 6 months according to the 2009 ELN criteria. This is an observational retrospective study.

Enrollment: 148 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start.

• Diagnosis criteria of PV :

  • WHO criteria of PV with :

    • Acquired JAK2V617F mutation > 5%
    • Absence of evident cause of secondary polycythemia

• Diagnosis criteria of ET :

  • Platelet count > 450 G/L
  • Absence of PV or Chronic Myeloid Leukemia
  • Bone marrow biopsy preferred but not necessary in absence of reactional causes (CRP and ferritin levels normal) and/or presence of acquired JAK2V617F, CALR exon 9 or MPL exon 10

• Availability of RNA sample of total leukocytes before start of treatment.

Exclusion criteria

In absence of clonality marker, presence of secondary cause of :

• Thrombocytosis :

  • Inflammatory syndrom (CRP or SV increased)
  • Iron deficiency (decreased ferritin level or increased soluble transferrin receptor level)

• Polycythemia :

  • Increased or normal level of EPO in context of :

    • Hypoxia, respiratory insufficiency
    • Sleep apnea syndrome
    • Hyperaffin hemoglobin

• Absence of treatment by hydroxyurea

• Treatment by anagrelide, P32, pipobroman, interferon without subsequent hydroxyurea treatment.

• Concommitant treatment by other cancer chemotherapy (in a context of solid cancer for example).

• Diagnostic during transformation to acute leukemia

• Treatment by hydroxyurea during less than 6 months

• Bad observance of the cytotoxic treatment

Trial design

148 participants in 1 patient group

Patients

Description:

ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available

Treatment:

Biological: RNA sample of total leukocytes before start of treatment